We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022.
![](https://endogena.com/wp-content/uploads/2022/06/endogena_sven.jpg)
“I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company that has just entered clinical stage and is developing novel therapies that could bring a potential cure to devastating diseases such as Retinis pigmentosa” explains Sven. Sven Weiler, PhD, brings more than 20 years’ experience in the pharmaceutical industry. He has worked on a broad variety of different target classes as well as on phenotypic screens for various indications. Previously Sven has been the Head of Chemistry for Basilea Pharmaceutica with a focus on Oncology and Antibacterials. Before that he was the Chemistry Head for the Musculoskeletal Disease Area at Novartis. Welcome to the team Sven!